Hormone Replacement Therapy Flashcards
Estrogen Actions
Brain:
- Regulates areas that prepare body for reproduction,
- Helps to maintain stable temperature and avoid hot flashes
- May help protect memory
Breast:
- Programs glands to produce milk
- Promotes breast cancer
Liver and Heart:
- Helps to regulate production of cholesterol by the liver and thus to avoid artherosclerosis and heart attack
Uterus:
- Programs uterus to nourish a fetus
- Promotes cancer of the uterine lining
Bone
- Maintains density
Pre-Menopause
- Before menopause, ovaries produce estrogen and progesterone
- During year of ovarian estrogen production, women benefit from estrogenic activities:
- Protection against CV disease
- Estrogen prevents artherosclerotic lesion formation
- Prevention or reversal of bone loss (osteoporosis)
- Protection against CV disease
- With these protective effects, surely anyone would wish to continue benefits by taking replacement hormones
Menopause
- After menopause ovaries no longer produce estrogen and progesterone
- Average age of menopause in US is 51 years
- Preceded by perimenopausal transition of varying duration
- Common symptoms associated with estrogen deficiency
- Hot flushes
- Vaginal atrophy
- Sleep disturbances
Conjugated Equine Estrogen (CEE)
Premarin is commercial name for compound drug consisting primarily of conjugated estrogens used for hormone therapy
- Estrone (>50%), equilin (15-25%) and equilenin
- Estrogen molecules are conjugated (generally present with hydrophilic side-groups attached such as sulfate)
- Estrone sulfate is easily absorbed and converted to estradiol by body
Premarin is isolated from mare’s urine (PREgnant MARe’s urINe)
Prempro is Premarin (CCE) plus medroxyprogesterone acetate (MPA), a synthetic progesterone
Women’s Health Initiative Study
- 16,808 healthy postmenopausal women enrolled between 1993-1998 (planned duration 8 years)
- Treated daily with; 1) placebo, 2) estrogen alone (CEE; Premarin), or 3) estrogen and synthetic progesterone (CEE + MPA; Prempro)
- Women in estrogen alone study had prior hysterectomy
- Progestin reduced risk of endometrial (uterine) cancer by inducing or maintaining endometrial atrophy in women with uterus
- Women in estrogen alone study had prior hysterectomy
Women’s Health Initiative Study Stopped
- CEE + MPA study was stopped in July 2002 (average duration of 5.2 years) when researchers discovered that women taking CEE + MPA demonstrated health problems compared to women waking a placebo:
- Increased risk of stroke
- Increased risk of venous thromoembolic events
- Increased risk of invasive breast cancer
- Estrogen alone study was stopped in February 2004 (avaerage duration of 7.1 years) when researchers discovered that women taking CEE alone demonstrated health problems compared to women taking placebo:
Increased risk of stroke
Women’s Health Initiative Study Initial Results
- Study found that CEE + MPA conferred the following health benefits:
- Decreased risk of colorectal cancer
- Decreased risk of hip fractures
- However, because overall risk of adverse health conditions was 15% greater than benefit, United States Department of Health and Human Services made following recommendation in July 2002:
- “The USPTF recommends against the routine use of estrogen and progestin for the prevention of chronic conditions in post-menopausal women.”
Hazard Ratio
- In survival analysis hazard ratio is effect of explanatory variable (i.e., smoking) on the hazard (or risk) or an event (i.e., getting lung cancer)
- Hazard ratio is estimate of Relative Risk (RR)
- In statistics and mathematical epidemiology, relative risk is risk of event (or of developing a disease; i.e., lung cancer) relative to exposure (smoking)
- Relative risk is calculated as ratio of probability of the event occurring in exposed group (i.e., smokers) versus non-exposed group (i.e., non-smokers)
Calculating Hazard Ratio
In this example, a=20% b=80, and c=1, and d=99
How to interpret Relative Risk
- Smokers would be twenty times as likely as non-smokers to develop lung cancer
- Another term for relative risk is risk ratio because it is a ratio of risk in exposed group divided by the risk in unexposed group
RR=1: means there is no difference between the two groups
RR>1: means event is more likely to occur in experimental group than in control group
RR>1: means event is less likely to occur in experimental group than in control group
Cardiovascular disease (CHD) Hazard Ratio
Check the math: Hip Fracture hazard ratio=
Calculated hazard ration is presented with 95% confidence interval
Nominal 95% CI= 0.45 – 0.98
How do we know if the hazard ratio is statistically significant?
Associated CI excludes 1.00
How do we know if the hazard ratio is important medically?
In 10,000 women taking estrogen + progestin for 1 year, there will be 5 fewer hip fractures events than for women taking placebo (decreased)
Hip Fracture Hazard Ratio
Check the math: Hip Fracture hazard ratio=
Calculated hazard ration is presented with 95% confidence interval
Nominal 95% CI= 0.45 – 0.98
How do we know if the hazard ratio is statistically significant?
Associated CI excludes 1.00
How do we know if the hazard ratio is important medically?
In 10,000 women taking estrogen + progestin for 1 year, there will be 5 fewer hip fractures events than for women taking placebo (decreased)
Global Index Hazard Ratio
Represents first event for each participant among following:
- Cardiovascular disease
- Stroke
- Pulmonary embolism
- Breast cancer
- Endometrial cancer
- Colorectal cancer
- Hip fracture
- Death due to other causes
Global index is summary of overall balance of risks & benefits
- Result is highly dependent upon variables selected for inclusion
Global Index Hazard Ration Calculations
Check the math: Global Index Hazard ratio:
Calculated hazard ration is presented with 95% confidence interval
Nominal 95% CI= 1.03 – 1.28
How do we know if the hazard ratio is statistically significant?
Associated CI excludes 1.00
How do we know if the hazard ratio is important medically?
In 10,000 women taking estrogen + progestin for 1 year, there will be 19 more adverse reactions than for women taking placebo (170 per 10,000 versus 151 per 10,000; 170-159=19) risks outweigh benefits
Response to WHI Study
Annual prescriptions for hormone therapy in United States decreased dramatically after 2002 publication of WHI study